Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01625988 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2951742 in Participants With Migraine
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 218
- Enrollment target
NCT01625988: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT01625988 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 218 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01625988, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 218 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of LY2951742 in the prevention of migraine headache in migraineurs with or without aura during 3 months of treatment.
Primary Outcome
The criteria for a migraine headache was adapted from the standard International Headache Society (IHS) International Classification of Headache Disorders II guidelines 1.1 and 1.2 (ICHD-II, Cephalgia 2004). The definition of a migraine headache was a headache with or without aura, of ≥30 minutes (min) duration, and with both ("A" and "B") required features from the IHS ICHD-II definition. Required feature "A" includes at least 2 of the following headache characteristics: unilateral location, pu
Interventions
- DRUG Placebo
- DRUG LY2951742
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2012-06-28 |
| Est. Completion | 2013-09-18 |
| Phase | Phase 2 |
What the finished NCT01625988 record still lists
NCT01625988 is an interventional study that assigns participants to a tested intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01625988 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01625988 about?
NCT01625988 is a clinical study titled "A Study of LY2951742 in Participants With Migraine". To assess the efficacy and safety of LY2951742 in the prevention of migraine headache in migraineurs with or without aura during 3 months of treatment.
What is the current status of trial NCT01625988?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 218 participants. The study started on 2012-06-28. Estimated completion is 2013-09-18.
What interventions are being tested in trial NCT01625988?
The interventions under investigation include: Placebo (DRUG), LY2951742 (DRUG).
Who is sponsoring clinical trial NCT01625988?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01625988's enrollment target sits among peer trials
218 284th of 2000 higher than 1,715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04693858 · 218 participants · NA
Efficacy Trial of the CALM Intervention
- NCT05909202 · 218 participants · NA
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
- NCT06000761 · 218 participants · NA
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
- NCT06249126 · 218 participants · NA
Primary Subtalar Arthrodesis for Calcaneal Fractures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI